Suppr超能文献

[病例报告:一例曾被诊断为淋巴瘤的EML4-ALK阳性肺腺癌]

[A case report: an EML4-ALK positive lung adenocarcinoma diagnosed 
with lymphoma previously].

作者信息

Liu Li, Heng Wei

机构信息

Department of Respiratory Medicine, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.

出版信息

Zhongguo Fei Ai Za Zhi. 2015 Feb;18(2):89-91. doi: 10.3779/j.issn.1009-3419.2015.02.07.

Abstract

In recent years, with the deepening of the research of molecular biology, targeted therapy has become one of the trend of lung cancer treatment. The individualized treatment of lung cancer is attached great importance at present. Echinoderm microtubule associated protein like 4 anaplastic lymphoma kinase (EML4-ALK) as a new biological marker is a hot topic in the field of lung cancer treatment. Meanwhile, with the improvement of anticancer treatment and survival, the incidence of multiple primary carcinomas (MPC) has become increasingly. But the report that malignant lymphoma complicated with lung adenocarcinoma harboring EML4-ALK fusion gene in one individual is rare. Here, we report an EML4-ALK positive non-small cell lung cancer (NSCLC) in a patient previously diagnosed with T cell lymphoma and review literature on metachronous lung cancer complicating with lymphoma.

摘要

近年来,随着分子生物学研究的深入,靶向治疗已成为肺癌治疗的趋势之一。目前,肺癌的个体化治疗备受重视。棘皮动物微管相关蛋白样4-间变性淋巴瘤激酶(EML4-ALK)作为一种新的生物标志物,是肺癌治疗领域的研究热点。同时,随着抗癌治疗效果的提高和患者生存期的延长,多原发性癌(MPC)的发病率日益增加。但关于同一患者恶性淋巴瘤合并携带EML4-ALK融合基因的肺腺癌的报道较为罕见。在此,我们报告1例先前诊断为T细胞淋巴瘤的患者发生EML4-ALK阳性非小细胞肺癌(NSCLC),并复习关于异时性肺癌合并淋巴瘤的文献。

相似文献

本文引用的文献

4
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.克唑替尼与化疗用于治疗晚期 ALK 阳性肺癌。
N Engl J Med. 2013 Jun 20;368(25):2385-94. doi: 10.1056/NEJMoa1214886. Epub 2013 Jun 1.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验